期刊文献+

炎性细胞因子调节药物代谢酶的研究进展 被引量:1

Research Progress of the Regulation of Drug Metabolism Enzymes by Inflammatory Cytokines
下载PDF
导出
摘要 炎症状态下许多重要的药物代谢酶表达及活性发生下调,药物代谢酶表达及活性的改变直接影响机体对药物的处置过程,导致药物不良反应的发生。大量研究表明,炎症反应中机体会释放大量的细胞因子,而其中某些炎性细胞因子参与下调药物代谢酶的表达及活性,其中细胞色素P450酶首当其冲。由于细胞因子对细胞色素P450酶的调节作用与炎症的发展程度以及疾病的治疗进程有关,临床上很难预测这种调节作用的结果。因此,弄清炎症情况下细胞因子对药物代谢酶的调节作用对分析和解释临床上发生的药物不良反应具有重要意义。本文综述了炎症状态下细胞因子对细胞色素P450酶的调控研究进展,探讨了其可能的作用机制以及临床意义。 The expression and activity of many important drug metabolizing enzymes were dramatically down regu- lated during inflammation, and these down regulation would directly affect the treatment process of drugs, resulting in side effects or even adverse reactions. A large number of studies indicated that large amounts of cytokines were released during inflammation and some inflammatory cytokines were involved in down regulation of the expression and activity of drug me- tabolizing enzymes, especially cytochrome P450 enzymes. Since the regulation of cytokines of cytochrome P450 was closely related to the degree of inflammation and the development and.treatment of diseases, so it was difficult to predict the results of this regulation, clarify the regulation of cytokines on drug metabolizing enzymes during inflammationwas important to ana- lyze and interpret drug adverse reactions in clinic. This paper summarized the progress of the research on the regulation of CYP450 in the inflammatory state, and discussed its possible mechanism and clinical significance.
出处 《药物流行病学杂志》 CAS 2016年第1期23-26,共4页 Chinese Journal of Pharmacoepidemiology
基金 国家自然科学基金资助项目(编号:81301953)
关键词 炎症反应 细胞因子 细胞色素P450 Inflammation response Cytokines CytochromeP450enzymes
  • 相关文献

参考文献34

  • 1Dickmann LJ, Patel SK, Rock DA, et al. Effects of inter- leukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture[ J]. Drug Metab Dispos,2011, 39(8) : 1415-1422.
  • 2Dallas S, Chattopadhyay S, Sensenhauser C, et al. Interleu- kins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepato- eytes[J]. Drug Metab Dispos,2013, 41(4) : 689-693.
  • 3Gorski JC, Hall SD, Becker P, et al. In vivo effects of in- terleukin-10 on human cytochrome P450 activity [ J ]. Clin Pharmacol Ther ,2000 , 67(1): 32-43.
  • 4Sunman JA, Hawke RL, Lecluyse EL, et al. Kupffer cell- mediated IL-2 suppression of CYP3A activity in human hepa- tocytes[J]. Drug Metab Dispos,2004, 32(3) : 359-363.
  • 5Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation [J]. Annu Rev Pharmacol Toxicol , 2006 , 46:123-149.
  • 6Aitken AE, Morgan ET. Gene-specific effects of inflammato- ry cytokines on cytoehrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes [ J ]. Drug Metab Dispos,2007, 35(9) : 1687-1693.
  • 7Li AP, Yang Q, Vermet H, et al. Evaluation of human hep- atocytes under prolonged culture in a novel medium for the maintenance of hepatic differentiation: results with the model pro-inflammatory cytokine interleukin 6. [ J ]. Drug Metabo- lism Letters,2014, 8(1) : 12-18.
  • 8Paszti-Gere E, Matis G, Farkas O, et al. The Effects of In- testinal LPS Exposure on Inflammatory Responses in a Por- cine Enterohepatic Co-culture System [ J ]. Inflammation, 2014, 37(1) : 247-260.
  • 9Sanada H, Sekimoto M, Kamoshita A, et al. Changes in ex- pression of hepatic cytochrome P450 subfamily enzymes dur- ing development of adjuvant-induced arthritis in rats [ J ]. J Toxicol Sci,2011, 36(2) : 181-190.
  • 10Nyagode BA, Lee CM, Morgan ET. Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in in- terleukin-6- and interferon- { gamma } -null mice [ J ]. J Phar- macol Exp Ther, 2010, 335(2) : 480-488.

二级参考文献17

  • 1Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases [ J ]. Chemico-biological interactions, 2006, 162(3) : 195-211.
  • 2Tully DB, Bao W, Goetz AK, et al. Gene expression profi- ling in liver and testis of rats to characterize the toxicity of triazole fungicides [ J ]. Toxicology and applied pharmacolo- gy,2006, 215(3) : 260-273.
  • 3Zhu W, Song L, Zhang H, et al. Dexamethasone differenti- ally regulates expression of carboxylesterase genes in humans and rats [ J ]. Drug metabolism and Disposition, 2000, 28 (2) : 186-191.
  • 4Shi D, Yang J, Yang D, et al. Dexamethasone suppresses the expression of multiple rat carboxylesterases through tran- scriptional repression: evidence for an involvement of the glucocorticoid receptor[J]. Toxicology,2008, 254( 1 ) : 97- 105.
  • 5Yang J, Yan B. Photochemotherapeutic agent 8-methoxypso- ralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X recep- tor[J]. Toxicol Sci, 2007, 95(1): 13-22.
  • 6尚伟,王宇文,吴丽丽,等.氟西汀抑制HepG2细胞HCEl,HCE2和CYP3A4的作用及其机制研究[J].中国科技论文在线,2014(在线发表).
  • 7Rosenfeld JM, Vargas Jr R, Xie W, et al. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor[ J]. Molecular Endocrinology, 2003, 17(7): 1268-1282.
  • 8Xu C, Wang X, Staudinger J L. Regulation of tissue-specif- ic carboxylesterase expression by pregnane x receptor and constitutive androstane receptor [ J ]. Drug Metabolism and Disposition, 2009, 37(7): 1539-1547.
  • 9Xu J, Li Y, Chen WD, et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis [ J ]. Hepatology, 2014, 59 ( 5 ) : 1761- 1771.
  • 10Furihata T, Hosokawa M, Masuda M, et al. Hepatocyte nu- clear factor-4α plays pivotal roles in the regulation of < i > mouse carboxylesterase 2 gene transcription in mouse liver [ J]. Archives of biochemistry and biophysics ,2006, 447(2) : 107-117.

共引文献1

同被引文献14

  • 1富晶,王虹艳,曲鹏.银杏叶提取物对脂多糖介导的血管内皮细胞低密度脂蛋白受体LOX-1表达的影响[J].大连医科大学学报,2006,28(5):378-380. 被引量:8
  • 2彭晋湘.动脉粥样硬化症的血管生物学进展及临床意义[J].西南国防医药,2007,17(1):109-111. 被引量:4
  • 3Hansson GK. Inflammation, atherosclerosis, and coronary artery dis- ease[ J]. N Engl J Meal,2005,353(4) :429-430.
  • 4Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s [ J ]. Nature, 1993,362 ( 6423 ) : 801-809.
  • 5Silva AP, Cavadas C, Baisse-Agushi B, et al. NPY, NPY receptors, and DPP IV activity are modulated by LPS ,TNF-a and IFN-g in HU- VEC [ J ]. Regulatory Peptides, 2003,116 ( 1 ) :71-79.
  • 6de Groot E,Hovingh GK, Wigeam A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis [ J ]. Circula- t/on,2004,109(23Supple 1 ) : Ⅲ33-Ⅲ38.
  • 7Libby P,Okamoto Y,Rocha VZ, et al. Inflammation in atherosclero- sis : transition from theory to practice [ J ] . CircJ, 2010,74 ( 2 ) : 213- 220.
  • 8John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic pa- tients : a randomized, placebo-controlled, double-blind study [ J ]. Cir- culation, 1998,98 ( 3 ) : 211-216.
  • 9Stancu C ,Toma L, Sima A. Dual role of lipoproteins inendothelial cell dysfunction in atherosclerosis [ J ]. Cell Tissue Res, 2012,349 ( 2 ) : 433-446.
  • 10王浩然,于春江.动脉粥样硬化发生机制及治疗药物的研究进展[J].首都医科大学学报,2010,31(6):828-833. 被引量:72

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部